CFO, Avita Medical
Dr Michelle Miller
CEO & MD, Biotron
Dr Paul Gavin
CEO, Avecho Biotech
Gary J Phillips
COVID-19 has put an increasing spotlight on biotechs. In this webinar we will aim to understand the risks and opportunities within the market landscape.
Understanding the business and investment case for biotech, as well as a deep dive into the featured companies.
Avecho developed a world first enhanced Vitamin E drug delivery platform TPM®, to improve the solubility and absorption of drugs. TPM® has the potential to increase effectiveness and reduce the side effects of drugs currently on the market. The company is also developing a CBD soft-gel capsule for insomnia.
Biotron is developing new drugs to much more effectively treat virus conditions such as SARS, HIV-1, influenza and dengue fever - ail very serious diseases. The company's lead drug shows potential as part of a combination therapy to eradicate HIV-1.
AVITA Medical is a regenerative medicine company with an innovative skin restoration technology platform RECELL ® positioned to address unmet needs in burns, chronic wounds, and aesthetics indications. ln the U.S., RECELL is indicated for the treatment of acute thermal burn wounds by an appropriately-licensed healthcare professional at the patient's point of care. ln addition to its burns business, AVITA Medical is currently conducting U.S. FDA pivotai trials in the usage of RECELL ® in soft tissue reconstruction and vitiligo, as well as pre-clinical research in the usage of RECELL ® for skin rejuvenation and the treatment of Epidermolysis Bullosa.
Pharmaxis' lead drug candidate is in clinical trials targeting the bone cancer myelofibrosis where it has disease modifying potential. Pharmaxis also has two FDA-approved products on market - Bronchitol® for respiratory disease cystic fibrosis and Aridol® for asthma.